98%
921
2 minutes
20
Synchronous multiple parathyroid carcinoma is a rare condition within the already uncommon landscape of parathyroid malignancies, which comprise less than 1% of sporadic primary hyperparathyroidism cases. To date, only seven cases of synchronous multiple parathyroid carcinoma in sporadic primary hyperparathyroidism have been documented. This exceptional rarity complicates both the diagnostic process and therapeutic decision-making. Clinically, parathyroid carcinoma typically presents as a single mass determining severe symptoms. However, no single clinical, biochemical, or imaging feature allows for definitive preoperative diagnosis. Imaging modalities such as ultrasound and sestamibi scans exhibit variable sensitivity and may overlook multi-gland involvement. Histopathological examination remains the only reliable diagnostic method. Management strategies are also controversial: while some advocate for conservative surgery, en bloc resection is generally recommended for its association with improved local control and disease-free survival. Given the exceptional occurrence of synchronous multiple parathyroid carcinoma, there is a lack of standardized protocols for managing parathyroid carcinoma in cases of synchronous and multiple gland involvement. Early multidisciplinary evaluation and individualized treatment planning are therefore crucial. This review aims to synthesize the presently available knowledge about synchronous multiple parathyroid carcinoma, assist clinicians with the limited data available, and discuss the main challenges in the management of this rare entity.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12347700 | PMC |
http://dx.doi.org/10.3390/jcm14155228 | DOI Listing |
Mol Imaging Radionucl Ther
September 2025
University Clinical Center of Serbia, Center for Nuclear Medicine with PET, Belgrade, Serbia.
Fluorine-fluorocholine (F-FCH) is a radiopharmaceutical used in primary hyperparathyroidism. The data about its utility in malignancies other than prostate and hepatocellular carcinoma is limited. We present the case of a patient who was referred for F-FCH positron emission tomography/computed tomography (PET/CT) due to the persistently elevated parathormone and calcium levels following total thyroidectomy with left lower parathyroidectomy for parathyroid carcinoma (PTC).
View Article and Find Full Text PDFClin Nucl Med
October 2025
Department of Nuclear Medicine, Centre Georges François Leclerc, Dijon, France.
Parathyroid carcinoma (PC) is a rare disease, with a frequency of 0.005% of all malignancies. Approximately 30% of patients will develop metastases at some point in the disease.
View Article and Find Full Text PDFBackground The accurate preoperative localization of parathyroid adenomas is crucial for minimally invasive parathyroidectomy (MIP) in primary hyperparathyroidism (PHPT). This study assessed the diagnostic performance of four-dimensional computed tomography (4D CT) in detecting parathyroid adenomas, compared with ultrasound (USG) and technetium methoxy isobutyl isonitrile single photon emission computed tomography (99mTc-sestamibi SPECT/CT). Methods We retrospectively analyzed 53 patients with biochemically confirmed PHPT who underwent all three preoperative imaging modalities, followed by parathyroidectomy from January 2020 to January 2025.
View Article and Find Full Text PDFArch Endocrinol Metab
September 2025
Hospital Universitário Clementino Fraga Filho/Universidade Federal do Rio de Janeiro Departamento de Clínica Médica Rio de Janeiro RJ Brasil Programa de Pós-graduação em Endocrinologia, Departamento de Clínica Médica, Hospital Universitário Clementino Fraga Filho/Universidade Federal do Rio
Primaryhyperparathyroidism (PHPT) is a disorder of mineral metabolism caused by inappropriate or excessive secretion of parathyroid hormone. It occurs sporadically in approximately 95% of cases but may also be associated with complex syndromes and/or a familial (i.e.
View Article and Find Full Text PDFEndokrynol Pol
September 2025
Department of Endocrinology and Radioisotope Therapy, Military Institute of Medicine - National Research Institute, Warsaw, Poland.
Introduction: Primary hyperparathyroidism (PHPT) is caused by excessive hormone secretion from one or more parathyroid glands. Based on their morphological and immunophenotypic characteristics, parathyroid glands can be considered as neuroendocrine organs, and their neoplasms as neuroendocrine tumors. The 2022 World Health Organization (WHO) Classification of Endocrine and Neuroendocrine Tumors introduced updated diagnostic criteria, advancing the understanding of parathyroid neoplasms.
View Article and Find Full Text PDF